P576 Therapeutic effects of mouse bone marrow-derived clonal mesenchymal stem cells in a mouse model of inflammatory bowel disease
CHA University, Gastroenterology, Seongnam, Korea, Republic of
Mouse bone marrow-derived clonal mesenchymal stem cells (mcMSCs), originated from a single cell by a subfractionation culturing method, are recognized as new paradigm for cell-based therapy.
Dextran sulfate sodium (DSS)-induced colitis was induced in C57BL/6 male mice by administrating 2.5 % DSS in a drinking water for 6 days. 4 × 105 cells mcMSCs were injected through tail vein on days 1, 3 and 5, respectively.
mcMSCs significantly reduced the DAI score, including weight loss, stool consistency, and intestinal bleeding, and significantly increased survival rates (p<0.01). The pathological scores were significantly improved with mcMSC (p<0.0001), especially mucosal regenerations accompanied with lesser apoptosis were significant beneficiary actions imposedby mcMSCs(p<0.001). The levels of inflammatory cytokines, including TNF-a, IFN-g, IL-1b, IL-6, and IL-17accompanied with NF-kB repression, were all significantly decreased in mcMSC treated group compared to the control group(p<0.01), and macrophage and neutrophil influx were significantly reduced (p<0.05).
mcMSCs showed significant therapeutic effects in experimental colitis through anti-inflammatory and restorative activities, are applicable as a potential source of cell-based therapy in IBD.